NIMESULIDE IS A NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) WITH ANTI-INFLAMMATORY, ANTI-PYRETIC, AND ANALGESIC PROPERTIES. IT INHIBITS PROSTAGLANDIN SYNTHETASE/CYCLOOXYGENASE, WHICH LIMITS PROSTAGLANDIN PRODUCTION. ITS CYCLOOXYGENASE INHIBITING POTENCY IS INTERMEDIATE, BUT IS RELATIVELY SELECTIVE FOR THE CYCLO-OXYGENASE-2 (COX-2) THUS THE POTENTIAL FOR GASTRIC INJURY AND INTOLERANCE IS LESS. IT IS ALSO A FREE RADICAL SCAVENGER, AND HELPS PROTECT AGAINST THE TISSUE DAMAGE THAT OCCURS DURING INFLAMMATION. ABSORPTION: WELL ABSORBED FROM GI TRACT FOLLOWING ORAL ADMIN. PEAK PLASMA LEVELS:1-3 HR. WITH BID ADMIN OF 100 MG, STEADY-STATE IS ACHIEVED WITHIN 24-36 HR. DISTRIBUTION: 99% BOUND TO PLASMA PROTEIN. METABOLISM: HEPATIC BIOTRANSFORMATION; PRINCIPAL METABOLITE IS 4-HYDROXY-NIMESULIDE. EXCRETION: ELIMINATION HALF-LIFE: 2-5 HR. METABOLITES IN URINE: 80%, FECES: 20% OF THE ADMINISTERED DOSE.9% BOUND TO PLASMA PROTEIN.

FOR USE OF REGISTERED MEDICAL PRACTITIONER OR A HOSPITAL ONLY